Two Sigma Advisers’s Ultragenyx Pharmaceutical RARE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
Sell
-481,600
Closed -$11.1M 1661
2025
Q4
$11.1M Sell
481,600
-36,100
-7% -$1.19M 0.02% 504
2025
Q3
$15.6M Sell
517,700
-342,700
-40% -$10.3M 0.03% 379
2025
Q2
$31.3M Sell
860,400
-76,800
-8% -$2.77M 0.06% 255
2025
Q1
$33.9M Buy
937,200
+23,700
+3% +$986K 0.08% 235
2024
Q4
$38.4M Sell
913,500
-74,300
-8% -$3.69M 0.09% 201
2024
Q3
$54.9M Buy
987,800
+545,600
+123% +$27.8M 0.13% 146
2024
Q2
$18.2M Sell
442,200
-6,000
-1% -$256K 0.04% 364
2024
Q1
$20.9M Buy
448,200
+259,300
+137% +$12.2M 0.05% 334
2023
Q4
$9.03M Sell
188,900
-40,600
-18% -$1.57M 0.02% 569
2023
Q3
$8.18M Sell
229,500
-261,000
-53% -$10.3M 0.02% 536
2023
Q2
$22.6M Sell
490,500
-7,400
-1% -$343K 0.06% 282
2023
Q1
$20M Buy
497,900
+37,200
+8% +$1.6M 0.05% 333
2022
Q4
$21.3M Buy
460,700
+409,300
+796% +$16.1M 0.06% 317
2022
Q3
$2.13M Buy
+51,400
New +$2.64M 0.01% 1140
2021
Q4
Sell
-69,400
Closed -$6.26M 2772
2021
Q3
$6.26M Sell
69,400
-68,500
-50% -$6.19M 0.02% 692
2021
Q2
$13.1M Buy
137,900
+5,800
+4% +$604K 0.03% 458
2021
Q1
$15M Buy
132,100
+72,400
+121% +$9.86M 0.04% 432
2020
Q4
$8.26M Buy
59,700
+22,300
+60% +$2.65M 0.02% 640
2020
Q3
$3.07M Sell
37,400
-1,900
-5% -$157K 0.01% 949
2020
Q2
$3.07M Buy
+39,300
New +$2.6M 0.01% 999
2016
Q1
Sell
-91,586
Closed -$10.3M 2118
2015
Q4
$10.3M Sell
91,586
-66,814
-42% -$6.68M 0.06% 313
2015
Q3
$15.4M Buy
158,400
+104,000
+191% +$11.9M 0.1% 246
2015
Q2
$5.57M Buy
54,400
+50,300
+1,227% +$3.91M 0.04% 444
2015
Q1
$255K Buy
+4,100
New +$228K ﹤0.01% 1645
2014
Q4
Sell
-9,800
Closed -$555K 2715
2014
Q3
$555K Buy
+9,800
New +$493K ﹤0.01% 1479

Other funds holding RARE